Results 111 to 120 of about 20,678 (258)

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain   +15 more
wiley   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu   +6 more
wiley   +1 more source

Comparison of DPP-4 Inhibitors

open access: yesThe Journal of Korean Diabetes, 2013
Nam Hoon Kim, Sin Gon Kim
openaire   +1 more source

Quality of Diabetes Care Among Older Adults in Germany—Results of the Study on Health of Older People 2022/2023 Compared With Previous National Health Surveys

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The study aims (1) to evaluate the quality of diabetes care considering guideline‐recommended medical therapies, cardiometabolic factors, and self‐management of health behaviours among older adults with diabetes in Germany, and (2) to examine time trends.
Yong Du   +6 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo   +3 more
wiley   +1 more source

The Upfront Effectiveness of a 6‐Week Continuous Glucose Monitoring Intervention for Non‐Insulin‐Using Individuals With Type 2 Diabetes Is No Longer Detectable at 6–12 Months: An Observational Follow‐Up of a Randomized Trial Cohort

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Jiawei Ryan Zhang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy